Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Randomized Controlled Study to Assess the Efficacy and Safety of rhTPO's Prophylactic Treatment of Cancer Treatment-induced Thrombocytopenia in Patients With High Risk of Treatment-induced Cardiac Injury

NCT05411705 is registered in ClinicalTrials.gov with The First Affiliated Hospital of Dalian Medical University as lead sponsor.

NCT NCT05411705
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05411705 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Randomized Controlled Study to Assess the Efficacy and Safety of rhTPO's Prophylactic Treatment of Cancer Treatment-induced Thrombocytopenia in Patients With High Risk of Treatment-induced Cardiac Injury
Lead sponsor
The First Affiliated Hospital of Dalian Medical University
Phase
Phase 4
Overall status
Unknown status
Start date
June 6, 2022
Completion date
August 31, 2024
Enrollment
165 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

cancer treatment induced thrombocytopenia